Literature DB >> 31918837

Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review.

Juan Guido Chiabrando1, Aldo Bonaventura2, Alessandra Vecchié2, George F Wohlford3, Adolfo G Mauro4, Jennifer H Jordan5, John D Grizzard6, Fabrizio Montecucco7, Daniel Horacio Berrocal8, Antonio Brucato9, Massimo Imazio10, Antonio Abbate11.   

Abstract

Pericarditis refers to the inflammation of the pericardial layers, resulting from a variety of stimuli triggering a stereotyped immune response, and characterized by chest pain associated often with peculiar electrocardiographic changes and, at times, accompanied by pericardial effusion. Acute pericarditis is generally self-limited and not life-threatening; yet, it may cause significant short-term disability, be complicated by either a large pericardial effusion or tamponade, and carry a significant risk of recurrence. The mainstay of treatment of pericarditis is represented by anti-inflammatory drugs. Anti-inflammatory treatments vary, however, in both effectiveness and side-effect profile. The objective of this review is to summarize the up-to-date management of acute and recurrent pericarditis.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute pericarditis; cardiac tamponade; constrictive pericarditis; recurrent pericarditis; treatment

Year:  2020        PMID: 31918837     DOI: 10.1016/j.jacc.2019.11.021

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  41 in total

Review 1.  Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.

Authors:  Kalyan R Chitturi; Ethan A Burns; Ibrahim N Muhsen; Kartik Anand; Barry H Trachtenberg
Journal:  Curr Oncol Rep       Date:  2022-02-22       Impact factor: 5.075

Review 2.  Cardiac inflammation and fibrosis following chemo/radiation therapy: mechanisms and therapeutic agents.

Authors:  Run Yang; Changming Tan; Masoud Najafi
Journal:  Inflammopharmacology       Date:  2021-11-23       Impact factor: 4.473

Review 3.  Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments.

Authors:  Emanuele Bizzi; Lucia Trotta; Massimo Pancrazi; Mariangela Nivuori; Valeria Giosia; Luca Matteucci; Daniela Montori; Antonio Brucato
Journal:  Curr Cardiol Rep       Date:  2021-07-28       Impact factor: 2.931

Review 4.  Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.

Authors:  Antonio Abbate; Stefano Toldo; Carlo Marchetti; Jordana Kron; Benjamin W Van Tassell; Charles A Dinarello
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 5.  What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.

Authors:  Marina Frayberg; Anthony Yung; Leyre Zubiri; Daniel A Zlotoff; Kerry L Reynolds
Journal:  Curr Treat Options Oncol       Date:  2021-05-26

6.  Idiopathic Effusive-Constrictive Pericarditis Presented by Variant Angina.

Authors:  Kentaro Adachi; Takaharu Hayashi; Takashi Omatsu; Atsushi Hirayama; Yoshiharu Higuchi
Journal:  Cureus       Date:  2021-04-09

7.  PE MIMICS: a structured approach for the emergency radiologist in the evaluation of chest pain.

Authors:  P J Dempsey; A Yates; J W Power; M C Murphy; J P Ko; B Hutchinson
Journal:  Emerg Radiol       Date:  2022-01-31

8.  Colchicine and the heart.

Authors:  Massimo Imazio; Mark Nidorf
Journal:  Eur Heart J       Date:  2021-07-21       Impact factor: 29.983

9.  Fifteen-year experience with pericardiectomy at a tertiary referral center.

Authors:  Zainab Faiza; Anjali Prakash; Niharika Namburi; Bailey Johnson; Lava Timsina; Lawrence S Lee
Journal:  J Cardiothorac Surg       Date:  2021-06-22       Impact factor: 1.637

10.  Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report.

Authors:  Ammar A Hasnie; Usman A Hasnie; Nirav Patel; Muhammad U Aziz; Min Xie; Steven G Lloyd; Sumanth D Prabhu
Journal:  BMC Cardiovasc Disord       Date:  2021-08-04       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.